![Page 1: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/1.jpg)
Annual report 2009: the state
of the drugs problem in Europe
NB Embargo 5 November 2009 10:00 CET (Brussels time)
![Page 2: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/2.jpg)
2
Latest on the drugs problem across Europe
• Overview of the European drug phenomenon in 30 countries
• Data and analyses: across Europe and by country
• Latest trends and responses
• Selected issues 2009 • Polydrug use: patterns and responses• Drug offences: sentencing and other
outcomes
![Page 3: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/3.jpg)
3
A multilingual information package
Annual report 2009 in 23 languages• http://www.emcdda.europa.eu/events/2009/annual-report
• Additional online material• Statistical bulletin • Country overviews • Selected issues• Reitox national reports
![Page 4: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/4.jpg)
4
Overview 2009
• Drug use levels still high in Europe
• But no major increases for most forms of use
• Amphetamine and ecstasy use: overall steady
• Cannabis: evidence of a decline in use, particularly in young people
• Cocaine and heroin maintain firm hold on Europe’s drug scene, with little sign of any recent improvement
• Polydrug use: now widespread and a growing issue for services
![Page 5: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/5.jpg)
5
Overview 2009
• New drugs: market innovation and sophistication
• Increasingly complex and volatile synthetic drug market
• Synthetic cannabinoids: latest in ‘designer drugs’
• Changes in the ecstasy market
• Signs of methamphetamine edging into new territory
![Page 6: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/6.jpg)
6
Part I
• Cocaine• Heroin• Cannabis• Polydrug use
![Page 7: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/7.jpg)
7
Cocaine, still Europe’s most popular stimulant
• Some 13 million European adults (15–64 years) have tried cocaine in their lifetime; some 4 million adults have used it in the last year
• Still concentrated in western EU countries, but elsewhere in Europe consumption is low
• Most reporting countries show a stable or rising trend in last-year use among young adults
• In Denmark, Spain, Ireland, Italy and the UK, last-year prevalence (15–34 years) ranges from 3.1 % to 5.5 %
• Seizures and studies raise concerns about potential for further diffusion
![Page 8: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/8.jpg)
8
Trends in last year prevalence of cocaine among young adults (aged 15–34), measured by population surveys Countries with three or more surveys
![Page 9: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/9.jpg)
9
Cocaine — more figures…
• Cocaine seizures rose to 92 000 in 2007 (84 000 in 2006)
• But the quantity seized dropped: to 77 tonnes in 2007 (121 tonnes in 2006)
• 22 % of those entering drug treatment for the first time cite cocaine as their primary drug
• Some 500 cocaine-related deaths were reported in 2007
![Page 10: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/10.jpg)
10
Heroin — trend no longer declining
• New data confirm last year’s analysis of ‘a stable, but no longer diminishing, problem’
• Concerns raised by three indicators of heroin use:• treatment demand• drug-induced deaths• seizures
• Not the epidemic spread of heroin problems seen in Europe in 1980s and 1990s
• But vigilance needed — heroin is still responsible for the largest share of drug-related health and social costs
![Page 11: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/11.jpg)
11
Warning signs (i): treatment demand
• Between 1.2 and 1.5 million problem opioid users (EU + Norway)
• New recruitment to heroin use is still occurring
• Number of new demands for treatment (heroin as the primary drug) was 6 % greater in 2007 than in 2002
• Eight countries reported that, between 2006 and 2007, users entering treatment for primary heroin use increased:
• in number and
• as a percentage of all clients
![Page 12: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/12.jpg)
12
Trend in estimated number of new clients entering treatment by primary drug used, from 2002 to 2007Numbers of clients by primary drug
![Page 13: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/13.jpg)
13
Warning signs (ii): drug-induced deaths
• In the period 1990–2006, between 6 400 and 8 500 drug-induced deaths were reported each year in Europe
• Most fatal overdoses are associated with opioids (typically over 85 %)
• Following an overall falling trend in drug-induced deaths between 2000 and 2003, subsequent data show an increase
• In 2007, 13 of the 18 reporting countries showed a rise
![Page 14: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/14.jpg)
14
Warning signs (iii): seizures
• Number of reported heroin seizures (EU + Norway) rose on average by around 4 % per year between 2002 and 2007
• Estimated 56 000 seizures in 2007 (51 000 in 2006)
• Amount of heroin seized (EU + Norway) declined after 2002, but increased from 8.1 tonnes in 2006 to 8.8 tonnes in 2007
• Turkey, important transit country for heroin entering EU, reported a record 13.2 tonnes seized in 2007 (2.7 tonnes in 2002)
![Page 15: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/15.jpg)
15
Cannabis — declining use
• Around 74 million Europeans (15–64 years) have tried cannabis in their lifetime; 41.5 million are young adults (15–34 years)
• 17 million young adults have used it in the last year
• But new data confirm last year’s assessment of overall declining popularity, particularly among young people
• The falling trend is particularly noticeable among schoolchildren
• School survey data from the USA and Australia also point to a decreasing trend since the early 2000s
![Page 16: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/16.jpg)
16
Cannabis — school students
• Different patterns in cannabis use among school students (15–16 years) across Europe (ESPAD surveys 1995, 1999, 2003, 2007)
• West European countries, as well as Croatia and Slovenia — a fall or stabilisation in lifetime cannabis use in 2007
• Central and east European countries — the increasing trend to 2003 may be levelling out (only Slovakia and Lithuania report a rise of over 3 %)
• Northern and southern Europe — overall more stable and low lifetime prevalence estimates of cannabis use from the mid to late 1990s to 2007
![Page 17: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/17.jpg)
17
Different patterns in trends in lifetime prevalence of cannabis use among 15- to 16-year-old school students
123
![Page 18: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/18.jpg)
18
Cannabis prevalence rates. Comparison of trends in average (unweighted) lifetime prevalence of cannabis (%) among 15-16 year old school students in Europe, USA and Australia
![Page 19: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/19.jpg)
19
Cannabis — young adults
• Last year cannabis use among young adults (15–34 years): generally a stabilisation or decline between 2002 and 2007
• But less encouraging is the number of regular and intensive cannabis users in Europe
• Up to 2.5 % of all young Europeans could be using cannabis on a daily basis
• A large population at risk and in potential need of treatment
• One example of innovative responses: Internet-based drug treatment interventions
![Page 20: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/20.jpg)
20
Trends in last year prevalence of cannabis among young adults
(aged 15–34), measured by national surveys
Countries with three or more surveys
![Page 21: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/21.jpg)
21
Polydrug use — patterns and responses
• Polydrug use, widespread in Europe
• Combined use of different substances is ‘responsible for, or complicates, most of the problems we face’
• Increases risks and complicates treatment delivery
• Alcohol present in almost all polydrug use repertoires
• ‘Selected issue’ — overview of this behaviour in: • schoolchildren (15–16 years)• young adults (15–34 years) • problem drug users
![Page 22: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/22.jpg)
22
Polydrug use — schoolchildren
• Of schoolchildren (15–16 years) surveyed in 22 countries:• 20 % reported use in the last month of alcohol with cigarettes• 6 % cannabis with alcohol and/or cigarettes• 1 % cannabis with alcohol and/or cigarettes plus at least one
other illicit drug (ecstasy, cocaine, amphetamines, LSD or heroin)
• Polydrug use can increase the risk of toxic effects and is associated with a greater risk of developing long-term problems
![Page 23: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/23.jpg)
23
Polydrug use — young adults
• Among young adults (15–34 years), polydrug use can reflect established patterns of substance use, potentially carrying long-term health problems, but also acute risk-taking during leisure time
• Frequent or heavy alcohol users in this age group were between two and six times more likely to have used cannabis in the last year than the general population
• And between two and nine times more likely to have used cocaine during that period
![Page 24: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/24.jpg)
24
Polydrug use — problem drug users
• Particularly prevalent among problem drug users
• Can aggravate their already difficult health conditions, leading to increased risk-taking and sometimes severe consequences
• In a recent analysis, over half (57 %) of those entering treatment reported problems with at least two different drugs
• Toxicology reports following fatal overdoses often show the presence of more than one substance
• Management of polydrug use among problem drug users is a complex task
![Page 25: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/25.jpg)
25
Part II
• Difficulties of ‘hitting a moving target’ • Detecting new drugs• Monitoring the Internet• ‘Spice’• Ecstasy• Methamphetamine
![Page 26: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/26.jpg)
26
Difficulties of ‘hitting a moving target’
• Market innovation and sophistication challenge drug policies
• Increasingly complex and volatile synthetic drug market
• Suppliers now ‘highly innovative’ in their production processes, product ranges and marketing
• ‘Growing sophistication’ in marketing legal alternatives to illicit drugs (so-called ‘legal highs’)
• Wide range of substances and growing use of the Internet
![Page 27: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/27.jpg)
27
Detecting new drugs
• Europe is making headway in detecting new drugs
• EU early-warning system (rapid-response mechanism set up in 1997), has tracked over 90 substances to date
• In 2008, 13 new psychoactive substances were reported by EU Member States to the EMCDDA and Europol
• For the first time, a synthetic cannabinoid, JWH-018, was among the reported drugs
• Synthetic cannabinoids — latest stage in the development of ‘designer drugs’
![Page 28: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/28.jpg)
28
Monitoring the Internet
• Monitoring the Internet — an ‘increasingly important element in identifying new drug trends’
• Now a major marketplace for psychoactive substances
• In 2009, the EMCDDA surveyed 115 online shops in 17 European countries
• Majority of the online retailers’ websites were registered in the UK (37 %), Germany (15 %), Netherlands (14 %) and Romania (7 %)
• Innovations of the online market include the creation of distinct brands and attractive packaging, a prime example being ‘Spice’
![Page 29: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/29.jpg)
29
Is ‘Spice’ the taste of things to come?
• Products marketed under the ‘Spice’ brand have been monitored through the early-warning system since early 2008
• Packaging information claims these are a blend of plant or herbal materials (often sold as incense), but some batches contain synthetic cannabinoids (e.g. JWH-018)
• These ingredients do not feature in the product information and may therefore be consumed unknowingly
• Some 48 % of the 115 online retailers surveyed were offering ‘Spice’
![Page 30: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/30.jpg)
30
Changes in the ecstasy market
• Most ecstasy tablets analysed until 2007 typically contained MDMA or another ecstasy-like substance (e.g. MDA, MDEA)
• This may be changing in some EU countries: around half of the ‘ecstasy’ tablets recently seized or sold in Denmark and the Netherlands contained no MDMA (instead tablets contained mCPP)
• Changes in the ecstasy market may be the result of more successful efforts to prevent the diversion of precursors
• The shortage of PMK, a key precursor used to make MDMA, could be one explanation for the recent changes
![Page 31: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/31.jpg)
31
Methamphetamine edges into new territory
• Methamphetamine is yet to make significant inroads into the stimulant drug market in western Europe (cocaine or amphetamine still dominate)
• But some signs that methamphetamine is starting to edge into new territory (beyond Czech Republic)
• Methamphetamine problems have developed in Slovakia and the drug appears to be becoming more available in parts of northern Europe, such as Norway and Sweden
• Some new production sites appear to be located in Lithuania, whose geographical position may facilitate the importation of the methamphetamine precursor BMK from outside the EU
![Page 32: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/32.jpg)
32
Methamphetamine — Norway and Sweden
• In 2007, almost 4 500 seizures of methamphetamine, amounting to approximately 340 kg, were reported in Europe
• Norway, by far the highest number of seizures (1 284) and the largest amount of methamphetamine recovered (167 kg)
• The second largest amount of methamphetamine seized in Europe (51 kg) was in Sweden
• Methamphetamine production in Europe has traditionally taken place in small-scale kitchen laboratories in the Czech Republic
• Europol now reports some larger sites in other parts of Europe (e.g. Germany, the Netherlands)
![Page 33: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/33.jpg)
33
Seized meth-
amphetamine
production
facilities in
2008 and
main
trafficking
flows
![Page 34: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/34.jpg)
34
Part III
• Treatment today• Selected issue: Drug offences• Development of effective drug policies in
Europe and beyond
![Page 35: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/35.jpg)
35
Treatment From ‘one size fits all’ to targeted solutions
• Services for drug users are increasingly diversified and offered as part of an integrated package of care
• Harm-reduction and treatment interventions are often linked and offered by the same providers
• In 2007, some 650 000 opioid users were estimated to have received substitution treatment in Europe
• Treatment coverage is still uneven (e.g. limited access to treatment outside metropolitan areas, small proportion of substitution treatments are in eastern EU Member States)
• Integration of drug treatment into general health care can contribute to a broader provision of treatment
• More projects address needs of stimulant and cannabis users
![Page 36: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/36.jpg)
36
Trend in the number of clients receiving opioid substitution
treatment from 1993 to 2007 in the EU-27
0
100000
200000
300000
400000
500000
600000
700000
1993 1995 1997/1998 2001/2002 2003 2005 2007
Clie
nts
in s
ub
stitu
tion
trea
tmen
t
![Page 37: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/37.jpg)
37
Drug offences: sentencing and other outcomes
• Little is known about the outcomes of drug offences
• Selected issue — a step towards filling this information gap
• Explores what happens to those who violate drug laws in 26 countries
• Examines national statistics (police, prosecutors, courts) according to: • type of offence (personal use, supply) • type of outcome (fine, custody, treatment, community work)
• Custodial sentences are rarely handed out for drug use or possession but are common for supply-related offences
![Page 38: Annual report 2009: the state of the drugs problem in Europe](https://reader036.vdocuments.net/reader036/viewer/2022062309/56815a6e550346895dc7cd59/html5/thumbnails/38.jpg)
38
Development of effective drug policies in Europe and beyond
• The European Union and the United Nations have both renewed their drug action plans
• Both highlight the importance of monitoring and evaluation to improve drug policies
• Almost all EU Member States have a national drug strategy
or action plan
• Two thirds of them plan to evaluate these policy documents